GALAPAGOS news, videos and press releases - Page 3
For more news please use our advanced search feature.
GALAPAGOS - More news...
GALAPAGOS - More news...
- Galapagos’ CEO makes donation of €10 million in the form of personal shares to African Parks
- Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial
- Selvita to acquire Fidelta from Galapagos
- First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
- OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis
- Galapagos reports Q3 2020 results
- EUROPEAN MEDICINES AGENCY VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF ULCERATIVE COLITIS
- Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
- PHASE 2B/3 TRIAL SHOWS EFFICACY OF FILGOTINIB FOR THE INDUCTION AND MAINTENANCE OF REMISSION IN MODERATELY AND SEVERELY ACTIVE ULCERATIVE COLITIS
- EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ACTIVE RHEUMATHOID ARTHRITIS
- Correction: Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
- Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
- Galapagos increases share capital through subscription right exercises
- Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients
- Galapagos to present new insights in IPF and related clinical developments at the European Respiratory Society Congress
- Galapagos announces that Gilead received a complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis
- NEW ANALYSES OF PHASE 2 EQUATOR CLINICAL PROGRAM SUPPORT DURABLE EFFICACY OF FILGOTINIB IN PSORIATIC ARTHRITIS
- Galapagos increases share capital through subscription right exercises
- Important update to Galapagos’ invitation to its ordinary and extraordinary shareholders’ meetings
- Galapagos and Ryvu Announce Research Collaboration
- Transformational year for Galapagos
- Orphan Drug Designation for GLPG1690 in systemic sclerosis
- Fibrocor and Galapagos sign expanded collaboration in fibrosis
- Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis
- Galapagos increases share capital through warrant exercises
- Galapagos receives transparency notification from Wellington Management Group LLP
- Galapagos increases share capital through warrant exercise by Gilead
- Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%
- MOR106 clinical development in atopic dermatitis stopped for futility
- GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS
